Market Overview

Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate

Share:
Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate
Related CARA
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American ... (GuruFocus)

Cara Therapeutics Inc (NASDAQ: CARA), a biotech company developing non-opioid pain relief drugs, has earned a bullish review from Jefferies. 

The Analyst

Analyst Matthew Andrews initiated coverage of Cara with a Buy rating and $30 price target.

The Thesis

Cara's lead program is intravenous Korsuva, which is being tested in chronic kidney disease on hemodialysis-associated pruritis, or CKD-HD-aP, Andrews said in the initiation note. (See his track record here.)

The drug has a promising opportunity given that 180,000 patients in the U.S. suffer from the disease and there is no FDA-approved drug, the analyst said. 

Jefferies estimates peak penetration for Korsuva at 27 percent and peak-adjusted U.S. sales of $573 million.

The CR845 Phase 2/3 study for Korsuva met its primary endpoint by reducing the Worst Itch-Numeric Rating Scale, or WI-NRS, by 3.8 points at Week 8 from the baseline relative to a placebo, Andrew said. 

Based on the data, the candidate was granted breakthrough therapy designation.

Andrews forecast a high likelihood of success in two similar Phase 3 U.S. and global studies initiated in January and December.

The top-line data from the Phase 3 studies, due in mid-2019, is likely to be Cara's next key catalyst, the analyst said. 

A Phase 2/3 study of IV CR845 showed statistically significant pain relief with reduced opioid-related side-effects in post-operative acute pain, according to Jefferies. 

The Price Action

Cara shares have jumped about 70 percent year-to-date.

The shares were rallying 2.19 percent to $21.31 at the time of publication Thursday.

Related Links:

4 Cannabis Stocks In Uptrends This Week

The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Latest Ratings for CARA

DateFirmActionFromTo
Sep 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018JefferiesInitiates Coverage OnBuy
Aug 2018Canaccord GenuityMaintainsBuyBuy

View More Analyst Ratings for CARA
View the Latest Analyst Ratings

Posted-In: Jefferies Matthew AndrewsAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

 

Related Articles (CARA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AMTDMorgan StanleyUpgrades65.0
APOMorgan StanleyDowngrades34.0
ARMKBairdUpgrades44.0
CGMorgan StanleyDowngrades23.0
EIXEdward JonesDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Day Market Update: Crude Oil Down Over 2%; Progenics Pharmaceuticals Shares Plunge

South Korea Might Be The First Country To Activate The Mass-Market Adoption Of Blockchain Technology